Project acronym 20SInhibitor
Project Selective 20S proteasome inhibition for multiple myeloma therapy
Researcher (PI) Michal SHARON
Host Institution (HI) WEIZMANN INSTITUTE OF SCIENCE
Call Details Proof of Concept (PoC), ERC-2018-PoC
Summary Multiple myeloma (MM) is a cancer of plasma cells, that is incurable, and the second most common form of blood cancer. Proteasome inhibitors (PIs) are considered a mainstay in the treatment of MM and mantle cell lymphoma (MCL). Current drugs, based on PIs however, target the chymotrypsin-like activity of the 20S proteasome, and inhibit the activities of both the 20S and 26S proteasomes. Thus, it is possible that selective drug intervention specifically inhibiting only the 20S proteasomes will reduce toxicity, and minimize the deleterious side effects of the current therapeutic regimens.
Our preliminary work revealed a family of 20S proteasome inhibitors, which we termed Catalytic Core Regulators (CCRs) that selectively target the 20S proteasome rather than the 26S complex. Based on sequence motif and structural elements of the CCRs we have designed an artificial protein that is capable of inhibiting the 20S proteasome. We anticipate that these findings will lead to the design of synthetic proteins, peptides or peptidomimetic compounds targeting cancer cells more specifically. This specificity will pose the compounds in an attractive light for using them in various therapeutic applications.
What is exciting from the commercialization perspective, is that pharmaceutical research has switched to revisit the use of peptides as therapeutics. Pharmaceutical companies have seen the development of peptides as a promising direction to lower their risk position. Overall, peptide therapeutics have a 20% chance of receiving regulatory approval, a probability that is 50% higher than that for the approval of small molecules, which form the basis of so called traditional drugs.
In the project, we will carry out actions, which will equip us with the sufficient IP protection strategy, business strategy, industry networks and initial contacts for taking the innovation out from the laboratory to next phase in developing therapy first for MM and MCL later on.
Summary
Multiple myeloma (MM) is a cancer of plasma cells, that is incurable, and the second most common form of blood cancer. Proteasome inhibitors (PIs) are considered a mainstay in the treatment of MM and mantle cell lymphoma (MCL). Current drugs, based on PIs however, target the chymotrypsin-like activity of the 20S proteasome, and inhibit the activities of both the 20S and 26S proteasomes. Thus, it is possible that selective drug intervention specifically inhibiting only the 20S proteasomes will reduce toxicity, and minimize the deleterious side effects of the current therapeutic regimens.
Our preliminary work revealed a family of 20S proteasome inhibitors, which we termed Catalytic Core Regulators (CCRs) that selectively target the 20S proteasome rather than the 26S complex. Based on sequence motif and structural elements of the CCRs we have designed an artificial protein that is capable of inhibiting the 20S proteasome. We anticipate that these findings will lead to the design of synthetic proteins, peptides or peptidomimetic compounds targeting cancer cells more specifically. This specificity will pose the compounds in an attractive light for using them in various therapeutic applications.
What is exciting from the commercialization perspective, is that pharmaceutical research has switched to revisit the use of peptides as therapeutics. Pharmaceutical companies have seen the development of peptides as a promising direction to lower their risk position. Overall, peptide therapeutics have a 20% chance of receiving regulatory approval, a probability that is 50% higher than that for the approval of small molecules, which form the basis of so called traditional drugs.
In the project, we will carry out actions, which will equip us with the sufficient IP protection strategy, business strategy, industry networks and initial contacts for taking the innovation out from the laboratory to next phase in developing therapy first for MM and MCL later on.
Max ERC Funding
150 000 €
Duration
Start date: 2019-04-01, End date: 2020-09-30
Project acronym 3Dmaterials4Energy
Project Hierarchical Inorganic Nanomaterials as Next Generation Catalysts and Filters
Researcher (PI) Taleb Mokari
Host Institution (HI) BEN-GURION UNIVERSITY OF THE NEGEV
Call Details Proof of Concept (PoC), PC1, ERC-2016-PoC
Summary In the coming few decades, two major global grand challenges will continue to attract the attention of scientists and engineers in academia and industry: achieving clean water and clean energy. This PoC establishes the development of two prototypes, water oxidation catalyst and water purification filter, by creating inexpensive, abundant and versatile hierarchical structures of inorganic nanomaterials (HSINs).
The formation of HSINs has been one of the major obstacles toward achieving a technological progress in various applications. Presently, fabrication of well-defined 3-D structures can be achieved either by photo/electro lithography, assembly, 3D printing or template-mediated methods. Various structures with high quality/yield can be obtained through those techniques, however, these methods suffer from high cost, difficulty of fabrication of free-standing structures, and sometime the throughput is limited. On the other hand, the templated approaches usually are facile, low cost and offer several and complex structures in particular the ones obtained from nature.
Our invention is based on forming the HSINs using fossil templates from nature. We propose to harness the naturally designed morphologies of the fossil templates to rationally form hierarchical structures of nanomaterials. These structures have many advantageous, compared to the current state-of-the-art catalyst and filter, for example high surface area, high porosity, confined space (nano-reactor) and divers functionalities obtained by controlling the chemical composition of the inorganic material shell. Since these properties are important for achieving high performance, we propose HSINs as next generation water oxidation electrocatalyst and water purification filter.
Summary
In the coming few decades, two major global grand challenges will continue to attract the attention of scientists and engineers in academia and industry: achieving clean water and clean energy. This PoC establishes the development of two prototypes, water oxidation catalyst and water purification filter, by creating inexpensive, abundant and versatile hierarchical structures of inorganic nanomaterials (HSINs).
The formation of HSINs has been one of the major obstacles toward achieving a technological progress in various applications. Presently, fabrication of well-defined 3-D structures can be achieved either by photo/electro lithography, assembly, 3D printing or template-mediated methods. Various structures with high quality/yield can be obtained through those techniques, however, these methods suffer from high cost, difficulty of fabrication of free-standing structures, and sometime the throughput is limited. On the other hand, the templated approaches usually are facile, low cost and offer several and complex structures in particular the ones obtained from nature.
Our invention is based on forming the HSINs using fossil templates from nature. We propose to harness the naturally designed morphologies of the fossil templates to rationally form hierarchical structures of nanomaterials. These structures have many advantageous, compared to the current state-of-the-art catalyst and filter, for example high surface area, high porosity, confined space (nano-reactor) and divers functionalities obtained by controlling the chemical composition of the inorganic material shell. Since these properties are important for achieving high performance, we propose HSINs as next generation water oxidation electrocatalyst and water purification filter.
Max ERC Funding
150 000 €
Duration
Start date: 2017-03-01, End date: 2018-08-31
Project acronym 3DPRINTEDOPTICS
Project 3D printed micro- and nano-optics for future integrated vision and endoscopy systems
Researcher (PI) Harald Giessen
Host Institution (HI) UNIVERSITAET STUTTGART
Call Details Proof of Concept (PoC), ERC-2019-PoC
Summary Optics is abundant in today’s world. Smartphone cameras, optical sensors for autonomous driving, virtual and augmented reality, medical imaging technology, and many more areas all require tailored optical sensors. In most cases, the optical sensors are still based on classical optical systems. For instance, high-end cameras or high-quality endoscopes still utilize classical glass optics. The related markets have sizes of several tens of billion USD and grow with double digit rates.
For all applications, size is the limiting factor. There is a tremendous demand for imaging capabilities using optics at sizes below 1 mm, with the quality of classical optics, i.e., correction of aberrations, extremely high transmission, and broadband operation. Key features include also zooming, focusing, and f-number variation, as well as customized fields of view to realize foveated imaging and multi-aperture, multi-lens systems. Ideally, such optical systems provide 180° field of view with simultaneous zooming capabilities.
Here, we propose a novel type of micro-optics that is extremely flexible, can be created at demand, possesses unprecedented functionality, and delivers solutions to problems that could not be solved before.
The basic building block at the heart of our problem solution is the use of 3D printed microoptics by femtosecond direct laser writing. This method has all features to fulfil the above-mentioned requirements: It takes only a day from the idea to concept, optical design and simulation, and to manufacturing and testing, i.e., to generate a working prototype.
Our method will create a new class of optical elements, which enable the smallest microscope objective in the world on the tip of an optical fiber with unprecedented imaging accuracy and functionality, such as focusing and zooming capability.
Summary
Optics is abundant in today’s world. Smartphone cameras, optical sensors for autonomous driving, virtual and augmented reality, medical imaging technology, and many more areas all require tailored optical sensors. In most cases, the optical sensors are still based on classical optical systems. For instance, high-end cameras or high-quality endoscopes still utilize classical glass optics. The related markets have sizes of several tens of billion USD and grow with double digit rates.
For all applications, size is the limiting factor. There is a tremendous demand for imaging capabilities using optics at sizes below 1 mm, with the quality of classical optics, i.e., correction of aberrations, extremely high transmission, and broadband operation. Key features include also zooming, focusing, and f-number variation, as well as customized fields of view to realize foveated imaging and multi-aperture, multi-lens systems. Ideally, such optical systems provide 180° field of view with simultaneous zooming capabilities.
Here, we propose a novel type of micro-optics that is extremely flexible, can be created at demand, possesses unprecedented functionality, and delivers solutions to problems that could not be solved before.
The basic building block at the heart of our problem solution is the use of 3D printed microoptics by femtosecond direct laser writing. This method has all features to fulfil the above-mentioned requirements: It takes only a day from the idea to concept, optical design and simulation, and to manufacturing and testing, i.e., to generate a working prototype.
Our method will create a new class of optical elements, which enable the smallest microscope objective in the world on the tip of an optical fiber with unprecedented imaging accuracy and functionality, such as focusing and zooming capability.
Max ERC Funding
150 000 €
Duration
Start date: 2019-06-01, End date: 2020-11-30
Project acronym AbCURE_COPD
Project Antibody mediated clearance of senescent cells for treatment of COPD
Researcher (PI) Valery KRIZHANOVSKY
Host Institution (HI) WEIZMANN INSTITUTE OF SCIENCE
Call Details Proof of Concept (PoC), ERC-2017-PoC
Summary Chronic Obstructive Pulmonary Disease (COPD) is a group of chronic diseases characterized by airflow limitations in the lung. COPD is a critical international health problem. It is estimated to affect up to 600 million people worldwide and by 2020 it will become the third most frequent cause of death. In Europe alone, COPD affects up to 10% of people (i.e. more people than breast cancer and diabetes) and it takes the life of around 300,000 Europeans each year. Up to date, COPD has no cure as current treatments fail to halt the long-term decline in lung function. They are only able to delay its progression. Those treatments however, are associated with a variety of side effects some of which can be acute and even life threatening. Thus, COPD remains a disease with a significant unmet medical need.
In this project (acronymed AbCURE_COPD) we intend to carry out a set of necessary activities for the evaluation of a potentially groundbreaking approach for treating COPD. Our approach is focusing on antibody-mediated clearance of senescent cells which accumulate in tissues with age and contribute to multiple age-related diseases, including COPD. The goal of the PoC project is two-fold. (1) The first goal is to establish the technical feasibility of our idea by testing the effect of senescence-specific antibodies on COPD development and progression by implementing COPD mouse model we developed. (2) The second goal is to establish the business feasibility of our revolutionary approach by taking the necessary steps towards its commercialization, focusing on the creation of strategic alliances with key private sector companies. We firmly believe that with our approach we can significantly extend the health span and improve the quality of life of COPD patients. Equally important, our approach will pave the way for the development of novel treatment strategies applicable to other age-related diseases, such as osteoarthritis, cardiovascular, and neurodegenerative diseases.
Summary
Chronic Obstructive Pulmonary Disease (COPD) is a group of chronic diseases characterized by airflow limitations in the lung. COPD is a critical international health problem. It is estimated to affect up to 600 million people worldwide and by 2020 it will become the third most frequent cause of death. In Europe alone, COPD affects up to 10% of people (i.e. more people than breast cancer and diabetes) and it takes the life of around 300,000 Europeans each year. Up to date, COPD has no cure as current treatments fail to halt the long-term decline in lung function. They are only able to delay its progression. Those treatments however, are associated with a variety of side effects some of which can be acute and even life threatening. Thus, COPD remains a disease with a significant unmet medical need.
In this project (acronymed AbCURE_COPD) we intend to carry out a set of necessary activities for the evaluation of a potentially groundbreaking approach for treating COPD. Our approach is focusing on antibody-mediated clearance of senescent cells which accumulate in tissues with age and contribute to multiple age-related diseases, including COPD. The goal of the PoC project is two-fold. (1) The first goal is to establish the technical feasibility of our idea by testing the effect of senescence-specific antibodies on COPD development and progression by implementing COPD mouse model we developed. (2) The second goal is to establish the business feasibility of our revolutionary approach by taking the necessary steps towards its commercialization, focusing on the creation of strategic alliances with key private sector companies. We firmly believe that with our approach we can significantly extend the health span and improve the quality of life of COPD patients. Equally important, our approach will pave the way for the development of novel treatment strategies applicable to other age-related diseases, such as osteoarthritis, cardiovascular, and neurodegenerative diseases.
Max ERC Funding
150 000 €
Duration
Start date: 2018-11-01, End date: 2020-04-30
Project acronym ACTIVEPHANTOM
Project Active Organ Phantoms for Medical Robotics
Researcher (PI) Peer FISCHER
Host Institution (HI) MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
Call Details Proof of Concept (PoC), PC1, ERC-2016-PoC
Summary Robot-assisted and minimally invasive medical procedures are impacting medical care by increasing accuracy, reducing cost, and minimizing patient discomfort and recovery times after interventions. Developers of commercial robotic surgical systems and medical device manufacturers look for realistic phantoms that can be used in place of animal experiments or cadavers to test procedures and to train medical personnel. Existing phantoms are either made from hard materials, or they lack anatomical detail, and they are mainly passive and thus unrealistic.
Here, we use recently developed fabrication know-how and expertise within our ERC-funded research to develop the first active artificial urinary tract model that includes a kidney, a bladder, and a prostate. Rapid prototyping is combined with a fabrication step that we have developed to permit the incorporation of active elements, such as a peristaltic system and fluidic valves in the phantom. We have developed smart material composites that reproduce the mechanical and haptic properties, and that give ultrasound contrast indistinguishable from real organs, while permitting anatomical details to be reproduced with a mean error of as little as 500 microns.
Feedback from a major medical device company indicates that ours is a unique phantom with unprecedented accuracy for which there is a market. Within this POC grant we want to develop a complete prototype, and to demonstrate a series of medical interventions on the phantom, including endoscopic diagnostic procedures (cystoscopy and ureterorenoscopy) and endoscopic treatment procedures (laser lithotripsy). The grant will allow us to protect our know-how, identify further markets, and develop a commercialization strategy.
Overall, this project will generate the first active phantom system that permits the testing of surgical instruments and procedures, with a sizeable market potential.
Summary
Robot-assisted and minimally invasive medical procedures are impacting medical care by increasing accuracy, reducing cost, and minimizing patient discomfort and recovery times after interventions. Developers of commercial robotic surgical systems and medical device manufacturers look for realistic phantoms that can be used in place of animal experiments or cadavers to test procedures and to train medical personnel. Existing phantoms are either made from hard materials, or they lack anatomical detail, and they are mainly passive and thus unrealistic.
Here, we use recently developed fabrication know-how and expertise within our ERC-funded research to develop the first active artificial urinary tract model that includes a kidney, a bladder, and a prostate. Rapid prototyping is combined with a fabrication step that we have developed to permit the incorporation of active elements, such as a peristaltic system and fluidic valves in the phantom. We have developed smart material composites that reproduce the mechanical and haptic properties, and that give ultrasound contrast indistinguishable from real organs, while permitting anatomical details to be reproduced with a mean error of as little as 500 microns.
Feedback from a major medical device company indicates that ours is a unique phantom with unprecedented accuracy for which there is a market. Within this POC grant we want to develop a complete prototype, and to demonstrate a series of medical interventions on the phantom, including endoscopic diagnostic procedures (cystoscopy and ureterorenoscopy) and endoscopic treatment procedures (laser lithotripsy). The grant will allow us to protect our know-how, identify further markets, and develop a commercialization strategy.
Overall, this project will generate the first active phantom system that permits the testing of surgical instruments and procedures, with a sizeable market potential.
Max ERC Funding
150 000 €
Duration
Start date: 2017-03-01, End date: 2018-08-31
Project acronym ACUSLABS
Project A new tool in drug development: mapping of compound-protein interaction using forward genetics
Researcher (PI) Martin DENZEL
Host Institution (HI) MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
Call Details Proof of Concept (PoC), ERC-2017-PoC
Summary Development of new medicines such as chemotherapeutic drugs requires a detailed understanding of their biological mechanism of action. What are the desired and undesired interactions with biological molecules? It is our goal to found a start-up company that will provide a solution to this challenge. Using novel and ground-breaking approaches we can identify target structures and interaction partners of small bioactive molecules at an unmatched and unprecedented resolution. ERC PoC funding will be essential to support our activities to identify optimal strategies and initial customers for our service.
Summary
Development of new medicines such as chemotherapeutic drugs requires a detailed understanding of their biological mechanism of action. What are the desired and undesired interactions with biological molecules? It is our goal to found a start-up company that will provide a solution to this challenge. Using novel and ground-breaking approaches we can identify target structures and interaction partners of small bioactive molecules at an unmatched and unprecedented resolution. ERC PoC funding will be essential to support our activities to identify optimal strategies and initial customers for our service.
Max ERC Funding
149 563 €
Duration
Start date: 2017-07-01, End date: 2018-12-31
Project acronym AIRWAVES
Project Automated high resolution water sampler for environmental monitoring
Researcher (PI) Dirk Sachse
Host Institution (HI) HELMHOLTZ ZENTRUM POTSDAM DEUTSCHESGEOFORSCHUNGSZENTRUM GFZ
Call Details Proof of Concept (PoC), ERC-2018-PoC
Summary A new automated water sampling technology was developed under the ERC Consolidator Grant STEEPclim with the potential to revolutionize environmental monitoring worldwide. A changing climate and growing scarcity of water strongly increase the need of reliable standardized and highly automated environmental monitoring, thus creating a growing market for our innovative solution. Our first prototype successfully operated under field conditions. Now we seek funding to further develop this device and explore commercialization pathways. Today, rain water, river discharge and climate are monitored routinely with high temporal resolution using quality sensors, but no adequate automated technology for obtaining representative samples for laboratory grade analysis is available for weather services, hydromet offices, chemical industry or research institutions. So far taking, preserving and analyzing samples from natural waters is meticulous, labor intensive and expensive. Isotope signatures in water are ideal tracers of processes in the water cycle. Stable isotope analysis of precipitation can identify changing atmospheric circulation patterns and the origin of groundwater. They can also be used for the reconstruction of paleoclimate from ancient waters locked in geological archives. The analysis of fruits, food and drink products, of drugs, explosives and human remains is used to identify their regional provenance. For this purpose a robust understanding of the modern distribution of isotopes in space and time is indispensable. The autonomous and robust sampler introduced here is designed to fulfill the high demands on sampling and storage for isotope analysis. It is portable, has low power consumption and can be accessed remotely for maintenance and to adapt the sampling protocol strategy. The obtained water samples are not restricted to isotope analysis but can be used for any type of environmental water analysis.
Summary
A new automated water sampling technology was developed under the ERC Consolidator Grant STEEPclim with the potential to revolutionize environmental monitoring worldwide. A changing climate and growing scarcity of water strongly increase the need of reliable standardized and highly automated environmental monitoring, thus creating a growing market for our innovative solution. Our first prototype successfully operated under field conditions. Now we seek funding to further develop this device and explore commercialization pathways. Today, rain water, river discharge and climate are monitored routinely with high temporal resolution using quality sensors, but no adequate automated technology for obtaining representative samples for laboratory grade analysis is available for weather services, hydromet offices, chemical industry or research institutions. So far taking, preserving and analyzing samples from natural waters is meticulous, labor intensive and expensive. Isotope signatures in water are ideal tracers of processes in the water cycle. Stable isotope analysis of precipitation can identify changing atmospheric circulation patterns and the origin of groundwater. They can also be used for the reconstruction of paleoclimate from ancient waters locked in geological archives. The analysis of fruits, food and drink products, of drugs, explosives and human remains is used to identify their regional provenance. For this purpose a robust understanding of the modern distribution of isotopes in space and time is indispensable. The autonomous and robust sampler introduced here is designed to fulfill the high demands on sampling and storage for isotope analysis. It is portable, has low power consumption and can be accessed remotely for maintenance and to adapt the sampling protocol strategy. The obtained water samples are not restricted to isotope analysis but can be used for any type of environmental water analysis.
Max ERC Funding
149 711 €
Duration
Start date: 2019-01-01, End date: 2020-06-30
Project acronym AllergenDetect
Project Comprehensive allergen detection using synthetic DNA libraries
Researcher (PI) Eran SEGAL
Host Institution (HI) WEIZMANN INSTITUTE OF SCIENCE
Call Details Proof of Concept (PoC), ERC-2018-PoC
Summary Over the last 50 years, allergies have become a major health issue affecting approximately 20% of adults and more than 30% of children in developed countries. Allergies impair the life quality of affected individuals and diagnosis/treatment is costly for health care systems. In the EU, the avoidable indirect costs of patients insufficiently treated for allergy is estimated to range between 55 and 151 billion Euro per year. A key issue towards fighting this allergy epidemic lies in the diagnosis of allergies, which is still limited by expensive, low throughput methods allowing to test only a few dozens of allergens at once. Yet, several thousands of allergens have been reported in the literature and cost effective methods for testing hundreds or even thousands of allergens are highly sought after.
Here, we propose a novel high throughput method (AllergenDetect) enabling to test more than 3000 protein allergens in parallel within a single test, relying on our ERC-funded technology. Instead of cumbersomely purifying protein allergens from natural sources, we will apply synthetic DNA libraries to produce allergens using expression systems commonly applied in biotechnology. Our method greatly expands the throughput of allergen testing compared to state of the art methods and allows for the first time to systematically test all known protein allergens at a fraction of today’s cost and within a single assay. In the first phase, we plan to market this technology as diagnostic kits to hospitals and analytic laboratories that have the required infrastructure already in place. For patient samples from private practitioners, specialized allergists, and individuals seeking allergy testing on their own, we are planning to launch a spin-off laboratory directly performing these AllergenDetect tests.
Summary
Over the last 50 years, allergies have become a major health issue affecting approximately 20% of adults and more than 30% of children in developed countries. Allergies impair the life quality of affected individuals and diagnosis/treatment is costly for health care systems. In the EU, the avoidable indirect costs of patients insufficiently treated for allergy is estimated to range between 55 and 151 billion Euro per year. A key issue towards fighting this allergy epidemic lies in the diagnosis of allergies, which is still limited by expensive, low throughput methods allowing to test only a few dozens of allergens at once. Yet, several thousands of allergens have been reported in the literature and cost effective methods for testing hundreds or even thousands of allergens are highly sought after.
Here, we propose a novel high throughput method (AllergenDetect) enabling to test more than 3000 protein allergens in parallel within a single test, relying on our ERC-funded technology. Instead of cumbersomely purifying protein allergens from natural sources, we will apply synthetic DNA libraries to produce allergens using expression systems commonly applied in biotechnology. Our method greatly expands the throughput of allergen testing compared to state of the art methods and allows for the first time to systematically test all known protein allergens at a fraction of today’s cost and within a single assay. In the first phase, we plan to market this technology as diagnostic kits to hospitals and analytic laboratories that have the required infrastructure already in place. For patient samples from private practitioners, specialized allergists, and individuals seeking allergy testing on their own, we are planning to launch a spin-off laboratory directly performing these AllergenDetect tests.
Max ERC Funding
150 000 €
Duration
Start date: 2019-05-01, End date: 2020-10-31
Project acronym ANALYTICS
Project All-electrical analytic platform for digital fluidics
Researcher (PI) Denys MAKAROV
Host Institution (HI) HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF EV
Call Details Proof of Concept (PoC), ERC-2017-PoC
Summary Prospective biosensing technologies will need to tackle the grand challenges arising from the global demographic changes. Among the most crucial tasks is the monitoring of food and environmental quality as well as the medical diagnosis. Digital fluidics offers vast advantages in performing these tasks relying on tiny containers with reacting biochemical species and allowing massively parallelized assays and high throughput screening using optical detection approaches.
I envision that adding not-optical detectors, which electrically probe the analyte responses, will provide a source of new but complementary information, obtained in a label-free and contactless manner. Hence, these all-electric platforms enable monitoring the kinetics of chemical reactions in lab-on-chip format, as well as take over auxiliary tasks, e.g. indexing, counting of droplets, flow monitoring.
In frame of the ERC project SMaRT, my team developed a unique detection platform -millifluidic resonance detector- that inductively couples to an analyte and assesses its physico-chemical properties. The unique selling points are (i) non-invasiveness to analyte, (ii) unnecessity of a transparent fluidic channel, (iii) cost efficiency and (iv) portability.
Implementing the input from the partner companies, here I aim to reach the commercialization stage pursuing a number of key milestones, i.e. enhance the screening throughput, realize a platform independent of external electronic devices, provide a temperature stabilization of the response, and develop the app.
Societal benefits: We demonstrated that the device provides an access to the metabolic activity of living organisms in droplets. This is way beyond the capabilities of the state-of-the-art optical detection. With this feature, the device can address the issue of increasing antibiotic resistance of bacteria and thus help to optimize the antibiotic policy in hospitals and households and to test new drugs in a time- and cost-efficient way.
Summary
Prospective biosensing technologies will need to tackle the grand challenges arising from the global demographic changes. Among the most crucial tasks is the monitoring of food and environmental quality as well as the medical diagnosis. Digital fluidics offers vast advantages in performing these tasks relying on tiny containers with reacting biochemical species and allowing massively parallelized assays and high throughput screening using optical detection approaches.
I envision that adding not-optical detectors, which electrically probe the analyte responses, will provide a source of new but complementary information, obtained in a label-free and contactless manner. Hence, these all-electric platforms enable monitoring the kinetics of chemical reactions in lab-on-chip format, as well as take over auxiliary tasks, e.g. indexing, counting of droplets, flow monitoring.
In frame of the ERC project SMaRT, my team developed a unique detection platform -millifluidic resonance detector- that inductively couples to an analyte and assesses its physico-chemical properties. The unique selling points are (i) non-invasiveness to analyte, (ii) unnecessity of a transparent fluidic channel, (iii) cost efficiency and (iv) portability.
Implementing the input from the partner companies, here I aim to reach the commercialization stage pursuing a number of key milestones, i.e. enhance the screening throughput, realize a platform independent of external electronic devices, provide a temperature stabilization of the response, and develop the app.
Societal benefits: We demonstrated that the device provides an access to the metabolic activity of living organisms in droplets. This is way beyond the capabilities of the state-of-the-art optical detection. With this feature, the device can address the issue of increasing antibiotic resistance of bacteria and thus help to optimize the antibiotic policy in hospitals and households and to test new drugs in a time- and cost-efficient way.
Max ERC Funding
150 000 €
Duration
Start date: 2017-09-01, End date: 2019-02-28
Project acronym aNtHESIS
Project Novel heart regeneration strategies
Researcher (PI) Eldad Tzahor
Host Institution (HI) WEIZMANN INSTITUTE OF SCIENCE
Call Details Proof of Concept (PoC), PC1, ERC-2014-PoC
Summary Heart disease and particularly myocardial infarction, i.e. heart attack, is the leading cause of death in the Western world today. The diminished regenerative potential of the heart begins shortly after birth, when most CardioMyocytes (CMs) cease to proliferate and make a transition from hyperplastic to hypertrophic growth. The Tzahor lab has been intensively exploring novel molecules, compounds as well as the molecular mechanisms that facilitate CM cell division in the adult heart of mammals as a strategy for eliciting heart regeneration. These efforts, had led to the identification of novel compounds which significantly increased the proliferation of adult CMs. Drawing upon these findings, the aim of the aNtHESIS project is two-fold. First, to (i) validate the pre-clinical application of our two novel compounds by conducting comprehensive in-vitro and in-vivo tests in mice as well as by carrying out experiments using human CMs. The second aim is (ii) to establish the business feasibility of our cardiac regenerative therapy concept by taking the necessary steps towards the commercialization of our novel compounds, focusing on the creation of strategic alliances with key private sector companies.
Summary
Heart disease and particularly myocardial infarction, i.e. heart attack, is the leading cause of death in the Western world today. The diminished regenerative potential of the heart begins shortly after birth, when most CardioMyocytes (CMs) cease to proliferate and make a transition from hyperplastic to hypertrophic growth. The Tzahor lab has been intensively exploring novel molecules, compounds as well as the molecular mechanisms that facilitate CM cell division in the adult heart of mammals as a strategy for eliciting heart regeneration. These efforts, had led to the identification of novel compounds which significantly increased the proliferation of adult CMs. Drawing upon these findings, the aim of the aNtHESIS project is two-fold. First, to (i) validate the pre-clinical application of our two novel compounds by conducting comprehensive in-vitro and in-vivo tests in mice as well as by carrying out experiments using human CMs. The second aim is (ii) to establish the business feasibility of our cardiac regenerative therapy concept by taking the necessary steps towards the commercialization of our novel compounds, focusing on the creation of strategic alliances with key private sector companies.
Max ERC Funding
150 000 €
Duration
Start date: 2016-01-01, End date: 2017-06-30
